• In Vitro Susceptibility of Staphylococci to Mupirocin and No

  2026-05-07

  This study systematically assessed the in vitro susceptibility of meticillin-resistant and meticillin-susceptible staphylococci from healthy and diseased dogs to mupirocin and novobiocin, identifying substantial efficacy yet variable resistance patterns among staphylococcal isolates. The findings inform evolving antimicrobial stewardship strategies in veterinary settings, emphasizing the need for ongoing susceptibility monitoring and comparative research.

• QSHXO Mitigates MASLD via Autophagy Activation and Ferroptos

  2026-05-06

  This study elucidates the dual mechanism by which Qushi Huoxue ointment (QSHXO) alleviates metabolic associated steatotic liver disease (MASLD), highlighting its activation of autophagy and suppression of ferroptosis in hepatocytes. These findings advance mechanistic understanding of MASLD therapy and provide a foundation for targeting cellular stress pathways in chronic liver disease.

• (S)-Mephenytoin: Transforming CYP2C19 Assays in Organoid Mod

  2026-05-06

  This thought-leadership article explores how (S)-Mephenytoin is accelerating the evolution of CYP2C19 substrate assays in advanced in vitro pharmacokinetic workflows, especially as hiPSC-derived intestinal organoids become the gold standard for human-relevant drug metabolism studies. Grounded in mechanistic evidence and strategic guidance, it highlights best practices, protocol parameters, and future implications for translational researchers.

• 2,5-di-tert-butylbenzene-1,4-diol (BHQ) in Calcium Signaling

  2026-05-05

  2,5-di-tert-butylbenzene-1,4-diol (BHQ) enables precise modulation of ER calcium dynamics, advancing both stem cell mobilization and vascular research. Recent breakthroughs highlight its pivotal role in enhancing hematopoietic stem cell yields, positioning BHQ as a transformative tool for calcium signaling investigations.

• Targeting FGFR2 Fusion in ICC via Heteroduplex Oligonucleoti

  2026-05-05

  This study introduces a cholesterol-conjugated DNA/RNA heteroduplex oligonucleotide (HDO) that specifically targets FGFR2 fusion oncogenes in intrahepatic cholangiocarcinoma (ICC). It demonstrates that combining targeted FGFR2 inhibition with asparagine deprivation can overcome resistance mechanisms, providing a rationale for new therapeutic strategies.

• E. coli Uracil-DNA Glycosylase (UDG): Practical Lab Applicat

  2026-05-04

  E. coli Uracil-DNA Glycosylase (UDG) is a recombinant enzyme designed for the removal of uracil from DNA, minimizing carryover contamination in PCR and supporting DNA repair research. It should be used exclusively in scientific research workflows and is not suitable for RNA substrates, diagnostic, or clinical applications.

• Flubendazole (SKU B1759) for Reliable Autophagy Modulation

  2026-05-04

  This article addresses persistent challenges in cell viability and autophagy assays by analyzing real laboratory scenarios where Flubendazole (SKU B1759) provides reproducible, data-backed solutions. Readers will learn when and why to use this high-purity, DMSO-soluble autophagy activator in cancer biology and neurodegenerative disease research, ensuring methodological rigor and workflow efficiency.

• Coumestrol: Phytoestrogen Estrogen Receptor Antagonist Advan

  2026-05-03

  Coumestrol’s dual role as a phytoestrogen estrogen receptor antagonist and inducer of ferroptosis in rheumatoid arthritis synoviocytes unlocks new frontiers for nuclear receptor and inflammation research. This article details protocol best practices, advanced assay applications, and troubleshooting insights, drawing from pivotal recent studies and APExBIO’s rigorously characterized product.

• Rapamycin (Sirolimus): Precision mTOR Inhibition in Cell Ass

  2026-05-02

  Rapamycin (Sirolimus) enables robust and targeted mTOR pathway inhibition for advanced research in cancer biology, immunology, and mitochondrial disease models. This guide translates recent mechanistic and workflow insights—including from TDG-ATF4-mTORC1 research—into actionable protocols and troubleshooting strategies for reproducible, high-impact experiments.

• Tiamulin (Thiamutilin): Comparative Metabolism and Assay Des

  2026-05-01

  Explore the unique metabolic pathways and practical assay implications of Tiamulin (Thiamutilin), a pleuromutilin antibiotic for veterinary use. This article provides a comparative perspective grounded in recent UHPLC–Q/TOF research, enabling more precise protocol design for infectious disease and anti-inflammatory models.

• HCN4 S4-S5 Linker Motif Drives Cardiac Heat Response Mechani

  2026-05-01

  Wu et al. (2023) reveal that a conserved S4-S5 linker motif in HCN4 channels is essential for heart rate acceleration in response to heat, independent of the classical cAMP binding pathway. This finding clarifies the molecular basis of temperature-induced cardiac excitability, offering a refined perspective for future studies on heart rate regulation.

• Letrozole: Mechanistic Leverage for Translational Oncology

  2026-04-30

  This thought-leadership article explores Letrozole’s mechanistic depth as a non-steroidal aromatase inhibitor, outlining its translational value for breast cancer researchers. We synthesize cutting-edge mechanistic insights, experimental best practices, and strategic guidance—highlighting how Letrozole from APExBIO enables precise estrogen biosynthesis inhibition and data-driven research innovation.

• Applied Insights: (-)-Blebbistatin in Non-Muscle Myosin II I

  2026-04-30

  (-)-Blebbistatin is redefining actin-myosin interaction inhibition with exceptional selectivity and reversibility, empowering high-resolution cytoskeletal and cardiac studies. This article demystifies its use-cases, experimental workflows, and expert troubleshooting, with actionable, data-driven guidance for maximizing reliability in advanced research.

• QSHXO Ameliorates MASLD via Autophagy Activation and Ferropt

  2026-04-29

  This study demonstrates that Qushi Huoxue ointment (QSHXO) mitigates metabolic associated steatotic liver disease (MASLD) by simultaneously activating autophagy and inhibiting ferroptosis in a mouse model. These findings clarify the mechanistic basis for QSHXO's therapeutic effects and provide insights into targeting cellular stress pathways in MASLD management.

• Screening MMV Pandemic Box Reveals Antifungal Leads for Cand

  2026-04-29

  This study systematically screened MMV Pandemic Response Box compounds against multidrug-resistant clinical isolates, highlighting several agents with potent activity against Candida species and other pathogens. The results inform antifungal research, particularly for tackling fluconazole-resistant and recurrent vulvovaginal candidiasis.

15620 records 1/1042 page Next 12345 下5页 Last page